The firm claims it has generated an extensive pipeline of potential blood biomarkers and made significant progress in developing and clinically validating ELISA assays for TBI. Banyan has secured over $70 million in grants for biomarker discovery, development, and clinical validation in fields spanning TBI, stroke, liver injury, and other serious diseases and disorders.